| First Author | Rojas JJ | Year | 2016 |
| Journal | Cell Rep | Volume | 15 |
| Issue | 2 | Pages | 264-73 |
| PubMed ID | 27050526 | Mgi Jnum | J:235090 |
| Mgi Id | MGI:5792770 | Doi | 10.1016/j.celrep.2016.03.017 |
| Citation | Rojas JJ, et al. (2016) Manipulating TLR Signaling Increases the Anti-tumor T Cell Response Induced by Viral Cancer Therapies. Cell Rep 15(2):264-73 |
| abstractText | The immune response plays a key role in enhancing the therapeutic activity of oncolytic virotherapies. However, to date, investigators have relied on inherent interactions between the virus and the immune system, often coupled to the expression of a single cytokine transgene. Recently, the importance of TLR activation in mediating adaptive immunity has been demonstrated. We therefore sought to influence the type and level of immune response raised after oncolytic vaccinia therapy through manipulation of TLR signaling. Vaccinia naturally activates TLR2, associated with an antibody response, whereas a CTL response is associated with TLR3-TRIF-signaling pathways. We manipulated TLR signaling by vaccinia through deglycosylation of the viral particle to block TLR2 activation and expression of a TRIF transgene. The resulting vector displayed greatly reduced production of anti-viral neutralizing antibody as well as an increased anti-tumor CTL response. Delivery in both naive and pre-treated mice was enhanced and immunotherapeutic activity dramatically improved. |
